Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2007-2-5
pubmed:abstractText
Preliminary evidence suggests that a single nucleotide polymorphism (SNP), the val108/158met SNP, within the gene that codes for catechol-O-methyltransferase (COMT), a key enzyme involved in regulating dopamine (DA) transmission within the prefrontal cortex (PFC), is related to cognitive function in schizophrenia and cognitive improvement with atypical antipsychotic drugs (APDs). Specifically, several studies have identified an association between working memory and executive functions, and COMT val108/158met genotype in schizophrenia; although there have been several negative findings that are likely related to small sample sizes and, possibly, medication status of patients at the time of testing. The association between COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine was investigated in a relatively large prospective sample of patients with schizophrenia, most of whom were unmedicated at baseline. Patients were genotyped for the COMT val108/158met SNP after completing a cognitive battery consisting of tests of attention, working memory, verbal learning and memory, executive function, and verbal fluency at baseline and after 6 weeks and 6 months of treatment with clozapine. Consistent with several previous studies, an association between COMT genotype and tests of executive function and working memory was identified at baseline. In addition, a novel interaction between genotype and improvement on tests of attention and verbal fluency was identified. Specifically, met homozygous and val/met heterozygous patients demonstrated significantly greater improvement than val homozygous patients following 6 months of treatment with clozapine. The results are discussed in relation to previous cross-sectional studies and prospective investigations of the associations between COMT genotype, cognition, and cognitive improvement with atypical APDs in schizophrenia.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0920-9964
pubmed:author
pubmed:issnType
Print
pubmed:volume
90
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
86-96
pubmed:dateRevised
2010-9-2
pubmed:meshHeading
pubmed-meshheading:17123785-Adult, pubmed-meshheading:17123785-Antipsychotic Agents, pubmed-meshheading:17123785-Catechol O-Methyltransferase, pubmed-meshheading:17123785-Clozapine, pubmed-meshheading:17123785-Cognition Disorders, pubmed-meshheading:17123785-Cohort Studies, pubmed-meshheading:17123785-Female, pubmed-meshheading:17123785-Follow-Up Studies, pubmed-meshheading:17123785-Genotype, pubmed-meshheading:17123785-Heterozygote, pubmed-meshheading:17123785-Homozygote, pubmed-meshheading:17123785-Humans, pubmed-meshheading:17123785-Male, pubmed-meshheading:17123785-Memory, Short-Term, pubmed-meshheading:17123785-Methionine, pubmed-meshheading:17123785-Neuropsychological Tests, pubmed-meshheading:17123785-Polymorphism, Single Nucleotide, pubmed-meshheading:17123785-Problem Solving, pubmed-meshheading:17123785-Prospective Studies, pubmed-meshheading:17123785-Schizophrenia, pubmed-meshheading:17123785-Treatment Outcome, pubmed-meshheading:17123785-Valine
pubmed:year
2007
pubmed:articleTitle
COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.
pubmed:affiliation
Department of Psychology, Vanderbilt University, Nashville, TN 37203, USA. neil.woodward@vanderbilt.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural